Association between osteopenia/osteoporosis and the serum RANKL in HIV-infected patients.
Mitsuru
M
Konishi
Ken
K
Takahashi
Eiichiro
E
Yoshimoto
Kenji
K
Uno
Kei
K
Kasahara
Keiichi
K
Mikasa
D000328:Adult; D000596:Amino Acids / Q000652:urine; D023241:Antiretroviral Therapy, Highly Active; D015519:Bone Density; D001851:Bone Diseases, Metabolic / Q000097:blood* / Q000503:physiopathology; D001862:Bone Resorption / Q000652:urine; D002352:Carrier Proteins / Q000097:blood*; D015658:HIV Infections / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D008297:Male; D008562:Membrane Glycoproteins / Q000097:blood*; D010024:Osteoporosis / Q000097:blood / Q000503:physiopathology; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B
D000596:Amino Acids; D002352:Carrier Proteins; D008562:Membrane Glycoproteins; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; C505686:TNFRSF11A protein, human; C505688:TNFSF11 protein, human; C036020:deoxypyridinoline